A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

479

Participants

Timeline

Start Date

June 17, 2021

Primary Completion Date

May 18, 2023

Study Completion Date

November 16, 2023

Conditions
Postmenopausal Women With Osteoporosis
Interventions
BIOLOGICAL

CT-P41

60 mg/mL single dose, Solution for injection in PFS

BIOLOGICAL

US-licensed Prolia

60 mg/mL single dose, Solution for injection in PFS

Trial Locations (20)

1012

Health Center 4-117 K. Barona Str, Riga

3401

Health Center Association, Medical Center Liepaja, Liepāja

10128

Center For Clinical And Basic Research, Tallinn

11312

East Tallinn Central Hospital-Ravi 18, Tallinn

21029

Clinic of SRI of Invalid Rehab. (ESTC) of VNMU n.a. M.I.Pyrohov, Vinnytsia

50106

Clinical Research Centre Ltd, Tartu

80010

KLV Arstikabinet, Pärnu

60-702

AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Poznaniu, Poznan

60-185

Centrum Medyczne Poznan - PRATIA - PPDS, Skórzewo

31-501

Krakowskie Centrum Medyczne, Krakow

50-381

AES - DRS - Synexus Polska Sp. z o.o. Oddzial we Wroclawiu, Wroclaw

90-368

SOMED CR Sp. z o.o. Sp. Komandytowa - Lodz, Lódz

01-192

AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warsaw

01-737

SOMED CR Sp. z o.o. Sp. Komandytowa - Warszawa, Warsaw

15-351

NZOZ Osteo Medic SC Artur Racewicz Jerzy Supronik, Bialystok

81-537

AES - DRS - Synexus Polska Sp. z o.o. Oddzial w Gdyni, Gdynia

30-510

MCM Krakow - PRATIA - PPDS, Krakow

02002

AES - AS - Medical Center of Edelweiss Medics LLC, Kyiv

04114

Clinic of SI Institute of Gerontology n.a. D.F.Chebotaryov of NAMS of Ukraine, Kyiv

Unknown

AES - AS - Medical Center of Medbud - Clinic LLC, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT04757376 - A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis | Biotech Hunter | Biotech Hunter